Fludrocortisone 0.1 Milligrams (mg)

ApprovedSmall molecule

Fludrocortisone 0.1 Milligrams (mg) is one of 29 small molecule programs targeting Adrenal insufficiency. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adrenal InsufficiencyActive, not recruiting

Ovarian Hyperstimulation SyndromeActive, not recruiting

Adrenal InsufficiencyApproved

Active, not recruiting

Ovarian Hyperstimulation SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Ovarian Hyperstimulation Syndrome

#DrugCompanyPhaseTrials

Medrol

Trelstar

3 3

Dostinex

Pfizer

Phase 3

8 4

Prometrium

Ferring

Approved

—5

Calcium Gluconate

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

2 6

Gnrh Ant

Merck & Co.

Phase 3

1 7

Calcium

Eli Lilly

Phase 3

1 8

Calcium Dobesilate

GGuizhou Bailing Group Pharmaceutical Co Ltd

Phase 3

2 9

Diosmin

TTanta University

Phase 3

1 10

Cetrotide

EMD Serono

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Hyperstimulation Syndrome1 trial

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

Completed·GGanin Fertility Center·Phase 2·NCT04351126·107 enrolled

Adrenal insufficiency1 trial

Ramadan Fasting Outcomes in Patients With Secondary Adrenal Insufficiency Before and After the Treatment of Hypotension.

Not yet recruiting·HHopital La Rabta·Phase 4·NCT06832566·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fludrocortisone 0.1 Milligrams (mg). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fludrocortisone 0.1 Milligrams (mg) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fludrocortisone 0.1 Milligrams (mg). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ganin Fertility Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGanin Fertility Center

Fludrocortisone 0.1 Milligrams (mg)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Hyperstimulation Syndrome1 trial

Adrenal insufficiency1 trial

References

Drug Info

Quick Facts

Related News